Calprotectin as a diagnostic tool for inflammatory bowel diseases

Area of Science:

• Gastroenterology
• Clinical Diagnostics
• Biochemistry

Background:

• Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are chronic conditions requiring ongoing patient monitoring.
• Current diagnostic methods like endoscopy involve invasive procedures and significant patient discomfort.
• There is a need for non-invasive, cost-effective diagnostic tools for IBD management.

Purpose of the Study:

• To review the potential of fecal calprotectin as a non-invasive biomarker for inflammatory bowel diseases.
• To evaluate calprotectin's utility in differentiating IBD from other gastrointestinal conditions.
• To assess the feasibility of using fecal calprotectin to reduce unnecessary endoscopies.

Main Methods:

• Review of existing literature on inflammatory bowel diseases and calprotectin.
• Analysis of calprotectin's stability and detectability in fecal samples.
• Comparison of calprotectin levels in IBD patients versus healthy controls.

Main Results:

• Calprotectin is elevated in the feces of IBD patients.
• Calprotectin is a stable biomarker detectable in small fecal sample volumes (<5 g).
• Fecal calprotectin shows promise as an inexpensive, non-invasive diagnostic marker for IBD.

Conclusions:

• Fecal calprotectin is a valuable non-invasive biomarker for inflammatory bowel diseases.
• This biomarker can aid in patient stratification and potentially reduce the frequency of invasive endoscopic procedures.
• Further research can establish fecal calprotectin's role in routine IBD diagnostics.